Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* CD20 and CD22-positive, B-cell NHL which has progressed after 1 or 2 prior therapies.~* Prior therapy must have contained at least one dose of Rituximab therapy. Patients can not be refractory to Rituximab (refractory = PD under treatment or within 6 month~* Eastern Cooperative Oncology Group (ECOG) performance status: 0/ 1.~* Patients must not have received previous radioimmunotherapy.~* Patients tolerant to Rituximab.~* Patients must not have received chemotherapy, cancer immunosuppressive therapy, growth factors (except erythropoietin), or investigational agents within 28 days before first dose of test article.~Exclusion Criteria:~* Candidate for potentially curative therapies~* Subjects must not have received previous radioimmunotherapy.~* Subjects with autologous hematopoietic stem cell transplant within the last 6 months

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Inotuzumab Ozogamicin + Rituximab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).